10589 Berlin, de
+49 (30) 726247-0
NOXXON Pharma appoints Dr. Joachim Kempeni as Chief Medical Officer
"Dr. Kempeni brings to NOXXON over two decades of professional experience in successful drug development, covering the full range of clinical and regulatory aspects of development," commented Dr. Sven Klussmann, NOXXON’s CEO and CSO. "We are very delighted to have a person with his expertise join our team and look forward to benefiting from his insight and leadership as we advance our products."
Dr. Walter Wenninger, Chairman of NOXXON’s supervisory board, commented: "Following our extensive search, we are privileged to have retained the services of an individual of Dr. Kempeni’s status. Dr. Kempeni’s broad experience and success in drug development add another dimension of leadership to NOXXON’s team. This mix will be crucial as the company moves forward its lead products."
Dr. Kempeni remarked on his appointment: "NOXXON’s Spiegelmers® are an exciting and tremendously promising new substance class. I am honored by the appointment and am convinced that my experience in driving drugs to the market in very different disease areas will be instrumental in exploiting the full potential of the company’s lead compounds NOX-E36 and NOX-A12."
Dr. Kempeni joined NOXXON from Astellas Pharma, where he served as Vice President of Research and Development Europe. In this function he was responsible for all of Astellas’ European R & D activities in the field of transplantation and antifungals and also served as General Manager of Astellas Germany. Dr. Kempeni was Vice President of Research and Development of Fujisawa Europe and as member of the management board responsible for all R&D activities of Fujisawa in Europe thereby covering a broad range of indications. Dr. Kempeni who has a degree in Biology and Medicine enjoyed a highly successful career at Knoll AG/BASF Pharma (now Abbott Europe) in the field of Oncology and Immunology, covering preclinical and clinical functions. One of his key achievements during his time at BASF was the fast track development of Humira, Abbott’s blockbuster antibody drug for the treatment of rheumatoid arthritis.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.